Base de dados : LILACS
Pesquisa : D02.540.505 [Categoria DeCS]
Referências encontradas : 76 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 8 ir para página                    

  1 / 76 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: biblio-1003722
Autor: Abarzúa C, Fernando; Rehren L, Karen; Díaz L, Tatiana; Feliú H, Raysa; Meissner S, Arturo; Muñoz R, Juan.
Título: Susceptibilidad antimicrobiana en muestras urogenitales de ureaplasma urealyticum, el principal agente en infección intramaniótica / Antimicrobial susceptibility in urogenital samples of ureaplasma urealyticum, the main agent in intramaniotic infection
Fonte: Rev. chil. obstet. ginecol. (En línea);84(1):49-54, feb. 2019. tab, graf.
Idioma: es.
Resumo: RESUMEN OBJETIVO: Ureaplasma urealyticum es el agente más frecuentemente aislado en infección intraamniótica. Los macrólidos son los antimicrobianos de primera elección en embarazadas. Se ha descrito el aumento de resistencia, pudiendo limitar las opciones terapéuticas durante la gestación. El propósito del estudio es evaluar susceptibilidad antimicrobiana de Ureaplasma urealyticum aislado en mujeres en edad fértil, que se atienden en Clínica Alemana Temuco, Araucanía, Chile. METODO: Se estudian todas las muestras de orina y flujo vaginal para cultivo de U. urealyticum, de pacientes entre 18 y 40 años, recibidas en el Laboratorio de Microbiología Clínica Alemana Temuco, en período Abril 2013 a Enero 2015. Se procesan las muestras con kit Mycoplasma IST 2 de Biomerieux. En las que resultan positivas, se estudia susceptibilidad a macrólidos, tetraciclinas y quinolonas. RESULTADOS: 426 muestras de orina y flujo vaginal (390 pacientes). 197 pacientes resultaron positivas para U. urealyticum. (50,5%). La susceptibilidad fue 88,4% (174 pctes) a Eritromicina, 87,9% (173 pctes) a Claritromicina y 91,9% (181 pctes) a Azitromicina (NS). 15 de 197 pacientes (7,6%) fueron resistentes a los 3 macrólidos. La susceptibilidad a Quinolonas fue 55,3% a Ciprofloxacino, y 94% a Ofloxacino. El 100% resultó susceptible a Tetraciclinas. CONCLUSIONES: Cerca del 10% de U. urealyticum aislados en nuestra serie son resistentes a macrólidos, contribuyendo a la no erradicación de la infección en tratamientos empíricos. Dentro de ellos, azitromicina aparece con la mayor efectividad. El aumento de resistencia limitará opciones terapéuticas, con gran impacto perinatal en futuro. La vigilancia de susceptibilidad en cada hospital es fundamental para elección terapéutica.

ABSTRACT INTRODUCTION: Ureaplasma urealyticum is the most frequently isolated microorganism in intra-amniotic infection. The macrolides are the first choice antimicrobials for treat this infection in pregnancy. The increasing resistance has been described worldwide, seriously limiting therapeutic options in pregnancy. The aim of the study is to evaluate antimicrobial susceptibility of U. urealyticum aislated in fertile-age women in Clínica Alemana Temuco, Araucania region, Chile. METHOD: Urine and vaginal samples were analyzed for U. urealyticum, from every 18 to 40 years old patients, received at Microbiology Laboratory of Clínica Alemana Temuco, between April 2013 to January 2015. The samples are processed with Mycoplasma IST 2 kit of Biomerieux. If they became positives, susceptibility to macrolides, tetracyclines and quinolones was studied. RESULTS: 426 urine and vaginal samples were collected (390 patients). 197 patients were positive for U. urealyticum (50.5%). The susceptibility was 88.4% (174 pts) to Erythromicyn, 87.9% (173 pts) to Clarithromycin and 91.9% (181 pts) to Azithromycin (NS). Resistance to all macrolides was observed in 15 out of 197 patients (7.6%). The susceptibility to Quinolones was 55.3% to Ciprofloxacin, and 94% to Ofloxacin. The 100% was susceptible to Tetracyclines. DISCUSSION: Near to 10% of isolated Ureaplasma spp in our serie were resistant to some macrolide, being a factor for failing to eradicate the infection in empirical treatment. Azithromycin was the most effective. The increasing resistance will limit therapeutic options, with great perinatal impact in the future. Susceptibility surveillance in each hospital is very important for therapeutic options.
Descritores: Ureaplasma/isolamento & purificação
Ureaplasma urealyticum/isolamento & purificação
Infecções por Ureaplasma/terapia
Macrolídeos/uso terapêutico
-Antibacterianos/uso terapêutico
Limites: Humanos
Feminino
Gravidez
Adolescente
Adulto
Responsável: CL126.2 - Biblioteca Médica Dr. Profesor Hernán Alessandri R.


  2 / 76 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1130684
Autor: Alí-Munive, Abraham; Prada-Romero, Leidy Paola; Rincón-Álvarez, Emily; Hernández-Parra, Ángela.
Título: Cardiovascular events related to the use of macrolides in an intensive care unit / Eventos cardiovasculares relacionados con el uso de macrólidos en una unidad de cuidado intensivo
Fonte: Acta méd. colomb;45(2):1-5, Jan.-June 2020. tab.
Idioma: en.
Resumo: Abstract Introduction and objectives: macrolides are widely used antibiotics for which a greater frequency of cardiovascular events related to increased arrhythmias has been reported. This study seeks to describe some cardiovascular complications of the use of macrolides in ICU patients. Materials and methods: this was a descriptive cross-sectional study which included adult patients admitted to the Medical Intensive Care Unit at the Fundación Cardioinfantil who received antibiotic treatment with clarithromycin in 2013 and 2015. Results: the collected sample was 38 patients. The median age was 64 years, and clarithromycin was most frequently used for treating community-acquired infections, with pneumonia being the most common diagnosis. The frequency of atrial fibrillation or flutter was 7.89%, and ventricular tachycardia 2.63%. The most frequently used concomitant medication was quetiapine at 28.95%. The main cause of death was respiratory failure. Conclusions: the frequency of arrhythmias was high in our study, although the most frequent cause of death was respiratory failure. (Acta Med Colomb 2020; 45. DOI:https://doi.org/10.36104/amc.2020.1336).

Resumen Introducción y objetivos: los macrólidos son antibióticos ampliamente utilizados con los cuales se ha reportado una mayor frecuencia de eventos cardiovasculares relacionados con aumento de arritmias. Mediante este estudio, se busca describir algunas complicaciones cardiovasculares con el uso de macrólidos en pacientes en UCI. Materiales y métodos: se realizó un estudio descriptivo de corte transversal en el que se incluyeron pacientes adultos que ingresaron a la unidad de cuidado intensivo médico de la Fundación Cardioinfantil y que recibieron tratamiento antibiótico con claritromicina durante los años 2013 y 2015. Resultados: la muestra recolectada fue de 38 pacientes, la mediana de edad fue de 64 años y la claritromicina se usó más frecuentemente en el tratamiento de infecciones adquiridas en la comunidad, siendo la neumonía el diagnóstico más común. La frecuencia de arritmias tipo fibrilación o flutter auricular fue de 7.89% y de taquicardia ventricular 2.63%. El medicamento concomitante más frecuentemente usado fue la quetiapina con 28.95%. La principal causa de muerte fue falla respiratoria. Conclusiones: la frecuencia de arritmias fue alta en nuestro, aunque la causa de muerte más frecuente fue falla respiratoria.(Acta Med Colomb 2020; 45. DOI:https://doi.org/10.36104/amc.2020.1336).
Descritores: Macrolídeos
-Pneumonia
Claritromicina
Fatores de Risco de Doenças Cardíacas
Unidades de Terapia Intensiva
Limites: Humanos
Masculino
Pessoa de Meia-Idade
Responsável: CO70 - Asociación Colombiana de Medicina Interna


  3 / 76 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Id: biblio-1171795
Autor: Reijtman Vanesa; Gagetti Paula; Faccone Diego; Fossati Sofía; Sommerfleck Patricia; Hernández Claudia; Bernáldez Patricia; Lopardo Horacio; Corso Alejandra.
Título: Macrolide resistance in Streptococcus pneumoniae isolated from Argentinian pediatric patients suffering from acute otitis media / Macrolide resistance in Streptococcus pneumoniae isolated from Argentinian pediatric patients suffering from acute otitis media.
Fonte: Rev. argent. microbiol;45(4):262-6, dic. 2013.
Idioma: es.
Resumo: Macrolide-resistant Streptococcus pneumoniae emerged in Argentina in 1995, representing 26

of invasive infection isolates in children under 5 years old. The objectives of this study were to describe the prevalence of ermB and mefA genes in macrolide-resistant S. pneumoniae isolates from acute otitis media (AOM) and to determine their genetic relatedness. Between May 2009 and August 2010, 126 S. pneumoniae isolates from 324 otherwise healthy children with a first episode of AOM were included. Twenty six of these isolates (20.6

) were resistant to erythromycin. Most frequent serotypes were: 14 (46.2

) and 9V (7.7

) carried the mefA gene, 5 (19.2

) have the ermB gene, and 1 (3.9

) both ermB + mefA. Ten clonal types were identified, mostly related to Sweden(15A)-25/ST782 (SLV63), CloneB(6A)/ST473 and England(14)-9/ ST9. This is the first study assessing the mechanisms of macrolide resistance in pneumococci isolates from pediatric AOM in Argentina and their genetic relatedness.
Descritores: Macrolídeos/farmacologia
Otite Média/microbiologia
Streptococcus pneumoniae/efeitos dos fármacos
-Antibacterianos
Argentina
Criança
Farmacorresistência Bacteriana
Humanos
Lactente
Pré-Escolar
Streptococcus pneumoniae/genética
Streptococcus pneumoniae/isolamento & purificação
Testes de Sensibilidade Microbiana
Tipo de Publ: Artigo de Revista
Research Support, Non-U.S. Gov't
Research Support, Non-U.S. Gov't
Research Support, Non-U.S. Gov't
Responsável: AR5.1 - Centro de Gestión del Conocimiento y las Comunicaciónes


  4 / 76 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1146034
Autor: Verdejo, Catalina; Vergara-Merino, Laura; Meza, Nicolás; Pérez-Bracchiglione, Javier; Carvajal-Juliá, Natalia; Madrid, Eva; Rada, Gabriel; Rojas Reyes, María Ximena.
Título: Macrólidos para el tratamiento de COVID-19: una revisión sistemática viva / Macrolides for the treatment of COVID-19: a living, systematic review
Fonte: Medwave;20(11), 31-12-2020.
Idioma: en.
Resumo: OBJETIVO Proporcionar un resumen oportuno, riguroso y continuamente actualizado de la evidencia disponible sobre el papel de los macrólidos para el tratamiento de pacientes con COVID-19. DIDEÑO Revisión Sistemática Viva. BASE DE DATOS: La búsqueda de evidencia se realizó en el repositorio centralizado L·OVE (Living OVerview of Evidence) COVID-19; una plataforma que mapea las preguntas PICO para identificar la evidencia en la base de datos Epistemonikos. En respuesta a la emergencia de COVID-19, L·OVE se adaptó para ampliar el rango de evidencia que cubre y hoy se mantiene a través de búsquedas regulares en 39 bases de datos. MÉTODOS: Se incluyeron estudios experimentales que evaluaban el efecto de los macrólidos, como monoterapia o en combinación con otros fármacos, versus placebo o ningún tratamiento en pacientes con sospecha o confirmación de COVID-19. Se buscó identificar experimentos clínicos aleatorizados que evaluaran macrólidos en infecciones causadas por otros coronavirus, como MERS-CoV y SARS-CoV. Dos revisores examinaron de forma independiente la elegibilidad de cada estudio, extrajeron los datos y evaluaron el riesgo de sesgo. Se evaluó el efecto de los macrólidos sobre la mortalidad por todas las causas; necesidad de ventilación mecánica invasiva; oxigenación por membrana extracorpórea, duración de la estancia hospitalaria, insuficiencia respiratoria, eventos adversos graves, tiempo hasta la negatividad de la RT-PCR del SARS-CoV-2. La certeza de la evidencia para cada desenlace se evaluó siguiendo la aproximación GRADE. Esta revisión se mantendrá viva y disponible abiertamente durante la pandemia de COVID-19. Se someterán actualizaciones de su publicación cada vez que cambien las conclusiones o cuando haya actualizaciones sustanciales. RESULTADOS: Se identificó un experimento clínico aleatorio que evaluó el uso de azitromicina en combinación con hidroxicloroquina en comparación con el uso de hidroxicloroquina sola, en pacientes hospitalizados por COVID 19. Las estimaciones para todos los resultados evaluados resultaron en un poder estadístico insuficiente para llegar a conclusiones válidas. La calidad de la evidencia para los resultados principales fue baja a muy baja. CONCLUSIONES: El uso de macrólidos en el tratamiento de pacientes con COVID 19 no ha mostrado efectos beneficiosos en comparación con el tratamiento estándar. La evidencia para todos los desenlaces no es concluyente. Se necesitan estudios sobre un mayor número de pacientes con COVID 19, para determinar los efectos del uso de macrólidos sobre los desenlaces relacionados con la enfermedad.

OBJECTIVE This living, systematic review aims to provide a timely, rigorous, and continuously updated summary of the evidence available on the role of macrolides for treating patients with COVID-19. DESIGN: a living, systematic review. DATABASE: We conducted searches in the centralized repository L·OVE (Living OVerview of Evidence). L·OVE is a platform that maps PICO questions to evidence from the Epistemonikos database. In response to the COVID-19 emergency, L·OVE was adapted to expand the range of evidence it covers and customized to group all COVID-19 evidence in one place. Today it is maintained through regular searches in 39 databases.METHODS: We included randomized trials evaluating the effect of macrolides ­ as monotherapy or in combination with other drugs ­ versus placebo or no treatment in patients with COVID-19. Randomized trials evaluating macrolides in infections caused by other coronaviruses, such as MERS-CoV and SARS-CoV, and non-randomized studies in COVID-19 were searched in case we found no direct evidence from randomized trials. Two reviewers independently screened each study for eligibility, extracted data, and assessed the risk of bias. Measures included all-cause mortality; the need for invasive mechanical ventilation; extracorporeal membrane oxygenation, length of hospital stay, respiratory failure, serious adverse events, time to SARS-CoV-2 RT-PCR negativity. We applied the GRADE approach to assess the certainty of the evidence for each outcome. A living, web-based version of this review will be openly available during the COVID-19 pandemic. We will resubmit it every time the conclusions change or whenever there are substantial updates. RESULTS: The search in the L·OVE platform retrieved 424 references. We considered 260 as potentially eligible and were reviewed in full texts. We included one randomized clinical trial that evaluated the use of azithromycin in combination with hydroxychloroquine compared to hydroxychloroquine alone in hospitalized patients with COVID 19. The estimates for all outcomes evaluated resulted in insufficient power to draw conclusions. The quality of the evidence for the main outcomes was low to very low. CONCLUSIONS: Macrolides in the management of patients with COVID 19 showed no beneficial effects compared to standard of care. The evidence for all outcomes is inconclusive. Larger trials are needed to determine the effects of macrolides on pulmonary and other outcomes in COVID-19 patients.
Descritores: Pneumonia Viral/tratamento farmacológico
Infecções por Coronavirus/tratamento farmacológico
Macrolídeos/uso terapêutico
-Pneumonia Viral/mortalidade
Respiração Artificial/estatística & dados numéricos
Ensaios Clínicos Controlados Aleatórios como Assunto
Resultado do Tratamento
Infecções por Coronavirus/mortalidade
Betacoronavirus/isolamento & purificação
Limites: Humanos
Tipo de Publ: Revisão Sistemática
Responsável: CL1.1 - Biblioteca Central


  5 / 76 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-789481
Autor: Pereira, Jussyêgles Niedja da Paz; Rabelo, Marcelle Aquino; Lima, Jailton Lobo da Costa; Neto, Armando Monteiro Bezerra; Lopes, Ana Catarina de Souza; Maciel, Maria Amélia Vieira.
Título: Phenotypic and molecular characterization of resistance to macrolides, lincosamides and type B streptogramin of clinical isolates of Staphylococcus spp. of a university hospital in Recife, Pernambuco, Brazil
Fonte: Braz. j. infect. dis;20(3):276-281, May.-June 2016. tab, graf.
Idioma: en.
Resumo: Abstract Introduction There is a mechanism of macrolide resistance in Staphylococcus spp. which also affects the lincosamides and type B streptogramins characterizing the so-called MLSB resistance, whose expression can be constitutive (cMLSB) or inducible (iMLSB) and is encoded mainly by ermA and ermC genes. The cMLSB resistance is easily detected by susceptibility testing used in the laboratory routine, but iMLSB resistance is not. Therapy with clindamycin in cases of infection with isolated iMLSB resistance may fail. Objective To characterize the phenotypic (occurrence of cMLSB and iMLSB phenotypes) and molecular (occurrence of ermA and ermC genes) profiles of MLSB resistance of clinical isolates of susceptible and methicillin-resistant Staphylococcus aureus and CNS (coagulase-negative Staphylococcus) from patients of a university hospital, in Pernambuco. Methods The antimicrobial susceptibility of 103 isolates was determined by the disk diffusion technique in Mueller–Hinton agar followed by oxacillin screening. The iMLSB phenotype was detected by D test. Isolates with cMLSB and iMLSB phenotypes were subjected to polymerase chain reaction (PCR) for the detection of ermA and ermC genes. Results The cMLSB and iMLSB phenotypes were respectively identified in 39 (37.9%) and five (4.9%) isolates. The iMLSB phenotype was found only in four (10.8%) methicillin-susceptible S. aureus and one (4.5%) methicillin-resistant S. aureus. In the 44 isolates subjected to PCR, four (9.1%) only ermA gene was detected, a lower frequency when compared to only ermC 17 (38.6%) gene and to one (2.3%) isolate presenting both genes. Conclusion In the Staphylococcus spp. analyzed, the ermC gene was found more often than the ermA, although the iMLSB phenotype had been less frequent than the cMLSB. It was important to perform the D test for its detection to guide therapeutic approaches.
Descritores: Staphylococcus/efeitos dos fármacos
Staphylococcus/genética
Macrolídeos/farmacologia
Estreptogramina B/farmacologia
Farmacorresistência Bacteriana Múltipla/genética
Lincosamidas/farmacologia
-Fenótipo
Brasil
Farmacorresistência Bacteriana Múltipla/efeitos dos fármacos
Testes de Sensibilidade a Antimicrobianos por Disco-Difusão
Genes Bacterianos/genética
Hospitais Universitários
Limites: Humanos
Responsável: BR1.1 - BIREME


  6 / 76 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: lil-491769
Autor: González V, Ramiro.
Título: Utilidad de los macrólidos en el manejo de las bronquiectasias: intervención a favor / Usefulness of macroles in the management of bronchiectasis: intervention in favor
Fonte: Rev. chil. enferm. respir;24(1):40-42, mar. 2008.
Idioma: es.
Descritores: Bronquiectasia/tratamento farmacológico
Macrolídeos/uso terapêutico
-Antibacterianos/uso terapêutico
Limites: Humanos
Responsável: CL1.1 - Biblioteca Central


  7 / 76 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: lil-491768
Autor: Herrera G, Ana María.
Título: Utilidad de los macrólidos el manejo de las bronquiectasias: intervención en contra / Usefulness of macroles the management of bronchiectasis: intervention against
Fonte: Rev. chil. enferm. respir;24(1):43-45, mar. 2008.
Idioma: es.
Descritores: Bronquiectasia/tratamento farmacológico
Macrolídeos/uso terapêutico
-Antibacterianos/uso terapêutico
Limites: Humanos
Tipo de Publ: Comentário
Responsável: CL1.1 - Biblioteca Central


  8 / 76 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1057399
Autor: Tumini, Melisa; Nagel, Orlando G; Althaus, Rafael L.
Título: Sistema microbiológico de cinco bioensayos para la detección de residuos de antibióticos / Five-assay microbiological system for the screeningf antibiotic residues
Fonte: Rev. argent. microbiol;51(4):345-353, dic. 2019. graf.
Idioma: en.
Resumo: Abstract A novel microbiological system in microtiter plates consisting of five bioassays is presented for the detection and classification of antibiotic residues in milk. The bioassays were optimized for the detection of beta-lactams (Bioassay B: Geobacillus stearothermophilus), macrolides (Bioassay M: Bacillus megaterium with fusidic acid), tetracyclines (Bioassay T: B. megaterium with chloramphenicol), quinolones (Bioassay Q: Bacillus licheniformis) and sulfamides (Bioassay QS: B. licheniformis with trimethoprim) at levels near the maximum residue limits (MRL). The response of each bioassay was interpreted visually (positive or negative) after 4-5.5h of incubation. The system detects and classifies beta-lactams (5 pg/l of amoxicillin, 4 pg/l of ampicillin, 36 pg/l of cloxacillin, 22 pg/l of amoxicillin, 3 pg/l of penicillin, 114 pg/l of cephalexin, 89pg/l of cefoperazone and 116 pg/l of ceftiofur), tetracyclines (98 pg/l of chlortetracycline, 92 pg/l of oxytetracycline and 88 pg/l of tetracycline), macrolides (33 pg/l of erythromycin, 44 pg/l of tilmicosin and 50 pg/l of tylosin), sulfonamides (76 pg/l of sulfadiazine, 85 pg/l of sulfadimethoxine, 77 pg/l of sulfamethoxazole and 87pg/l of sulfathiazole) and quinolones (94 pg/l of ciprofloxacin, 98 pg/l of enrofloxacin and 79 pg/l marbofloxacin). In addition, the specificity values were high for B, T, Q (99.4%), M (98.8%) and QS (98.1%) bioassays. The control of antibiotics through this system can contribute to improving the quality and safety of dairy products.

Resumen Se presenta un novedoso sistema microbiológico en placas de microtitulación compuesto por 5 bioensayos para la detección y clasificación de residuos de antibióticos en leche. Los bioensayos fueron optimizados para la detección de betalactámicos (bioensayo B: Geobacillus stearothermophilus), macrólidos (bioensayo M: Bacillus megaterium con ácido fusídico), tetraciclinas (bioensayo T: Bacillus megaterium con cloranfenicol), quinolonas (bioensayo Q: Bacillus licheniformis) y sulfamidas (bioensayo QS: Bacillus licheniformis con trimetoprima), a niveles cercanos a los límites máximos de residuos (LMR). La respuesta de cada bioensayo se interpretó visualmente (positiva o negativa) después de 4 a 5,5 h de incubación. El sistema detecta y clasifica betalactámicos (5 pg/l de amoxicilina, 4 pg/l de ampicilina, 36 pg/l de cloxacilina, 22 pg/l de amoxicilina, 3 pg/l de penicilina, 114 pg/l de cefalexina, 89 pg/l de cefoperazona y 116 pg/l de ceftiofur), tetraciclinas (98 pg/l de clortetraciclina, 92 pg/l de oxitetraciclina y 88 pg/l de tetraciclina), macrólidos (33 pg/l de eritromicina, 44 pg/l de tilmi-cosina y 50 pg/l de tilosina), sulfamidas (76 pg/l de sulfadiacina, 85 pg/l de sulfadimetoxina, 77 pg/l de sulfametoxazol y 87 pg/l de sulfatiazol) y quinolonas (94 pg/l de ciprofloxacina, 98 pg/l de enrofloxacina y 79pg/l de marbofloxacina). Además, los valores de especificidad fueron altos para los bioensayos B, T, Q (99,4%), M (98,8%) y QS (98,1%). El control de residuos de antibióticos mediante este sistema puede contribuir a mejorar la calidad e inocuidad de los productos lácteos.
Descritores: Bioensaio/métodos
Microbiologia de Alimentos/métodos
Antibacterianos/análise
-Sulfonamidas/análise
Tetraciclina/análise
Quinolonas/análise
Macrolídeos/análise
Laticínios
beta-Lactamas/análise
Tipo de Publ: Ensaio Clínico
Responsável: AR635.1 - FCVyS - Servicio de Información y Documentación


  9 / 76 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1122865
Autor: Oliveira, Paola Brandão Ferreira de; Lopes, Márcia Quinhones Pires; Pires, Marize Quinhones; Lora, Leonardo Barraza; Barros, Rosana Rocha; Suffys, Philip Noel; Nery, José Augusto; Gomes, Harrison Magdinier.
Título: Mixed infection and two different resistance profiles of to macrolides identified in some clinical specimens of the same patient / Infecção mista e resistência diferente a macrolídeos em Treponema pallidum identificadas por variadas espécimes clínicos em um mesmo paciente
Fonte: DST j. bras. doenças sex. transm;30(1):25-29, 30-03-2018.
Idioma: en.
Resumo: Syphilis represents a global public health problem. The resistance of Treponema pallidum to macrolides is related to the mutation in the 23S rRNA gene (A2058G). We reported a case of secondary syphilis in a 52-year-old man presenting two profiles: the first one of susceptibility, and the other one of resistance, when we analyzed the 23S rRNA gene sequence from two different clinical specimens of the same infectious episode. DNA from T. pallidum from skin biopsy presented resistance profile, whereas T. pallidum DNA from blood presented a profile of susceptibility to macrolides. These results suggest it was mixed infection or reinfection.

A sífilis representa um problema de saúde pública mundial. A resistência de Treponema pallidum aos macrolídeos está relacionada à mutação no gene 23S rRNA (A2058G). Relatamos um caso de sífilis secundária, em um homem de 52 anos, com um perfil de suscetibilidade e outro de resistência, ao analisarmos a sequência do gene 23S rRNA de dois espécimes clínicos diferentes, do mesmo episódio infeccioso. A amostra de DNA de T. pallidum proveniente de raspado dérmico da lesão apresentou um perfil de resistência, enquanto aquele que derivou de sangue apresentou perfil de suscetibilidade aos macrolídeos. Esses resultados sugerem tratar-se de infecção mista ou de reinfecção.
Descritores: Treponema pallidum
Sífilis
Macrolídeos
-Ferimentos e Lesões
DNA
Suscetibilidade a Doenças
Limites: Humanos
Tipo de Publ: Relatos de Casos
Responsável: BR2499


  10 / 76 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1042461
Autor: Molento, Marcelo Beltrão; Canever, Ricardo José.
Título: In vitro evaluation of ivermectin, moxidectin, albendazole and pyrantel against cyathostomins of horses / Avaliação in vitro da ivermectina, moxidectina, albendazole e pirantel contra ciatostomíneos de equinos
Fonte: Rev. bras. parasitol. vet;27(1):90-93, Jan.-Mar. 2018. tab, graf.
Idioma: en.
Resumo: Abstract Cyathostomins are the most prevalent nematodes of horses, and multidrug resistance has been reported worldwide. There is a need to implement alternative drug monitoring analytical tests. The objective of this study was to determine the consistency (5 repetitions) of the larval migration on agar test (LMAT) using ivermectin, moxidectin, pyrantel or albendazole against cyathostomin infective-stage larvae in eight different concentrations. LMAT showed a strong coefficient of determination (R2 > 0.91), between the test repetitions (n=5). The average 50% effective concentration (EC50) for ivermectin, moxidectin, pyrantel and albendazole were 0.0404, 0.0558, 0.0864 and 0.0988 nMol, respectively. The results of the EC50 for albendazole showed the greatest range of concentration. Ivermectin and moxidectin had the lowest in between-test variation. In the future, internationally certified susceptible isolates could be used for screening new drug candidates, or to follow up the pattern of drug efficacy from field populations.

Resumo Ciatostomíneos são os nematodas mais prevalentes em equinos e a resistência múltipla foi relatada em todo o mundo. Existe a necessidade de implementar o monitoramento dos produtos com testes analíticos alternativos. O objetivo deste estudo foi determinar a consistência (5 repetições) do teste de migração larval em ágar (TMLA) usando ivermectina, moxidectina, pirantel e albendazole contra larvas infectantes de ciatostomíneos em oito concentrações diferentes. O TMLA demonstrou um coeficiente de determinação (R2) acima de 0,91 entre as repetições do teste. A concentração efetiva para 50% (CE50) para ivermectina, moxidectina, pirantel e albendazole foi de 0,0404; 0,0558; 0,0864 e 0,0988 nMol, respectivamente. A CE50 do albendazole demonstrou a maior amplitude entre os testes. A ivermectina e a moxidectina tiveram as menores variações das doses entre as repetições. No futuro, isolados certificados susceptíveis poderão ser testados com o TMLA para indicação de novos produtos e mesmo para acompanhar o perfil de eficácia de populações do campo.
Descritores: Cavalos/parasitologia
Nematoides/efeitos dos fármacos
Antiparasitários/farmacologia
-Parasitologia/métodos
Pirantel/farmacologia
Ivermectina/farmacologia
Albendazol/farmacologia
Macrolídeos/farmacologia
Larva/efeitos dos fármacos
Limites: Animais
Responsável: BR1.1 - BIREME



página 1 de 8 ir para página                    
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde